Treating medullary thyroid cancer in the age of targeted therapy.
about
The treatment landscape in thyroid cancer: a focus on cabozantinibDemonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
P2860
Treating medullary thyroid cancer in the age of targeted therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Treating medullary thyroid cancer in the age of targeted therapy.
@ast
Treating medullary thyroid cancer in the age of targeted therapy.
@en
type
label
Treating medullary thyroid cancer in the age of targeted therapy.
@ast
Treating medullary thyroid cancer in the age of targeted therapy.
@en
prefLabel
Treating medullary thyroid cancer in the age of targeted therapy.
@ast
Treating medullary thyroid cancer in the age of targeted therapy.
@en
P2093
P2860
P356
P1476
Treating medullary thyroid cancer in the age of targeted therapy.
@en
P2093
Camilo Jimenez
Elizabeth G Grubbs
Gilbert J Cote
Maria E Cabanillas
P2860
P304
P356
10.2217/IJE.14.26
P577
2014-01-01T00:00:00Z